Phase II trial of topotecan for the treatment of mesothelioma

Andrew W. Maksymiuk, Robert F. Marschke, Henry D. Tazelaar, Joe Grill, Suresh Nair, Randolph Stuart Marks, B. Jay Brooks, James A. Mailliard, G. Mark Burton, James R. Jett

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The North Central Cancer Treatment Group designed a phase II trial to assess the efficacy and toxicity of topotecan in patients with unresectable malignant pleural mesothelioma. Twenty-two previously untreated patients with unresectable pleural mesothelioma and good performance status (Eastern Cooperative Oncology Group performance status 0, 1, or 2) were enrolled on this trial from October 1993 through July 1994. Nineteen men and three women, median age 66 years (range, 44-78 years), were treated with topotecan 1.5 mg/m2 intravenously over 30 minutes daily for 5 days at 3-week intervals until toxicity, progression of disease, or a patient decided to discontinue treatment. There were seven patients with measurable disease and 15 with evaluable disease; all were assessable for response and toxicity. A total of 113 cycles of treatment were given, for a median of three cycles (range, 1- 26 cycles). Myelosuppression was the most frequent toxicity. Eighteen of 21 patients (86%) experienced grade 3 or 4 neutropenia during the initial treatment cycle. The median neutrophil nadir was 0.5 x 103/μl (range, 0.11.6 x 103/μl), and the median platelet nadir was 127 x 103/μl (range, 18-460 X 103/μl). Other toxicities more than grade 2 included malaise (two patients), and anorexia, infection, fever, pulmonary, and cardiac in one patient each. There were no objective responses, and 18 patients had stable disease for a median of 74 days. The median survival for all patients was 230 days, with 23% alive at 1 year. Topotecan as administered in this trial is reasonably well tolerated; however, the response rate was insufficient to warrant additional study in pleural mesothelioma.

Original languageEnglish (US)
Pages (from-to)610-613
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume21
Issue number6
DOIs
StatePublished - Dec 1998

Fingerprint

Topotecan
Mesothelioma
Therapeutics
Anorexia
Neutropenia
Disease Progression
Neutrophils
Fever
Blood Platelets
Lung

Keywords

  • Mesothelioma
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of topotecan for the treatment of mesothelioma. / Maksymiuk, Andrew W.; Marschke, Robert F.; Tazelaar, Henry D.; Grill, Joe; Nair, Suresh; Marks, Randolph Stuart; Brooks, B. Jay; Mailliard, James A.; Burton, G. Mark; Jett, James R.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 21, No. 6, 12.1998, p. 610-613.

Research output: Contribution to journalArticle

Maksymiuk, AW, Marschke, RF, Tazelaar, HD, Grill, J, Nair, S, Marks, RS, Brooks, BJ, Mailliard, JA, Burton, GM & Jett, JR 1998, 'Phase II trial of topotecan for the treatment of mesothelioma', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 21, no. 6, pp. 610-613. https://doi.org/10.1097/00000421-199812000-00017
Maksymiuk, Andrew W. ; Marschke, Robert F. ; Tazelaar, Henry D. ; Grill, Joe ; Nair, Suresh ; Marks, Randolph Stuart ; Brooks, B. Jay ; Mailliard, James A. ; Burton, G. Mark ; Jett, James R. / Phase II trial of topotecan for the treatment of mesothelioma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1998 ; Vol. 21, No. 6. pp. 610-613.
@article{e821b076f7834513adbed5c3b8e0e513,
title = "Phase II trial of topotecan for the treatment of mesothelioma",
abstract = "The North Central Cancer Treatment Group designed a phase II trial to assess the efficacy and toxicity of topotecan in patients with unresectable malignant pleural mesothelioma. Twenty-two previously untreated patients with unresectable pleural mesothelioma and good performance status (Eastern Cooperative Oncology Group performance status 0, 1, or 2) were enrolled on this trial from October 1993 through July 1994. Nineteen men and three women, median age 66 years (range, 44-78 years), were treated with topotecan 1.5 mg/m2 intravenously over 30 minutes daily for 5 days at 3-week intervals until toxicity, progression of disease, or a patient decided to discontinue treatment. There were seven patients with measurable disease and 15 with evaluable disease; all were assessable for response and toxicity. A total of 113 cycles of treatment were given, for a median of three cycles (range, 1- 26 cycles). Myelosuppression was the most frequent toxicity. Eighteen of 21 patients (86{\%}) experienced grade 3 or 4 neutropenia during the initial treatment cycle. The median neutrophil nadir was 0.5 x 103/μl (range, 0.11.6 x 103/μl), and the median platelet nadir was 127 x 103/μl (range, 18-460 X 103/μl). Other toxicities more than grade 2 included malaise (two patients), and anorexia, infection, fever, pulmonary, and cardiac in one patient each. There were no objective responses, and 18 patients had stable disease for a median of 74 days. The median survival for all patients was 230 days, with 23{\%} alive at 1 year. Topotecan as administered in this trial is reasonably well tolerated; however, the response rate was insufficient to warrant additional study in pleural mesothelioma.",
keywords = "Mesothelioma, Topotecan",
author = "Maksymiuk, {Andrew W.} and Marschke, {Robert F.} and Tazelaar, {Henry D.} and Joe Grill and Suresh Nair and Marks, {Randolph Stuart} and Brooks, {B. Jay} and Mailliard, {James A.} and Burton, {G. Mark} and Jett, {James R.}",
year = "1998",
month = "12",
doi = "10.1097/00000421-199812000-00017",
language = "English (US)",
volume = "21",
pages = "610--613",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Phase II trial of topotecan for the treatment of mesothelioma

AU - Maksymiuk, Andrew W.

AU - Marschke, Robert F.

AU - Tazelaar, Henry D.

AU - Grill, Joe

AU - Nair, Suresh

AU - Marks, Randolph Stuart

AU - Brooks, B. Jay

AU - Mailliard, James A.

AU - Burton, G. Mark

AU - Jett, James R.

PY - 1998/12

Y1 - 1998/12

N2 - The North Central Cancer Treatment Group designed a phase II trial to assess the efficacy and toxicity of topotecan in patients with unresectable malignant pleural mesothelioma. Twenty-two previously untreated patients with unresectable pleural mesothelioma and good performance status (Eastern Cooperative Oncology Group performance status 0, 1, or 2) were enrolled on this trial from October 1993 through July 1994. Nineteen men and three women, median age 66 years (range, 44-78 years), were treated with topotecan 1.5 mg/m2 intravenously over 30 minutes daily for 5 days at 3-week intervals until toxicity, progression of disease, or a patient decided to discontinue treatment. There were seven patients with measurable disease and 15 with evaluable disease; all were assessable for response and toxicity. A total of 113 cycles of treatment were given, for a median of three cycles (range, 1- 26 cycles). Myelosuppression was the most frequent toxicity. Eighteen of 21 patients (86%) experienced grade 3 or 4 neutropenia during the initial treatment cycle. The median neutrophil nadir was 0.5 x 103/μl (range, 0.11.6 x 103/μl), and the median platelet nadir was 127 x 103/μl (range, 18-460 X 103/μl). Other toxicities more than grade 2 included malaise (two patients), and anorexia, infection, fever, pulmonary, and cardiac in one patient each. There were no objective responses, and 18 patients had stable disease for a median of 74 days. The median survival for all patients was 230 days, with 23% alive at 1 year. Topotecan as administered in this trial is reasonably well tolerated; however, the response rate was insufficient to warrant additional study in pleural mesothelioma.

AB - The North Central Cancer Treatment Group designed a phase II trial to assess the efficacy and toxicity of topotecan in patients with unresectable malignant pleural mesothelioma. Twenty-two previously untreated patients with unresectable pleural mesothelioma and good performance status (Eastern Cooperative Oncology Group performance status 0, 1, or 2) were enrolled on this trial from October 1993 through July 1994. Nineteen men and three women, median age 66 years (range, 44-78 years), were treated with topotecan 1.5 mg/m2 intravenously over 30 minutes daily for 5 days at 3-week intervals until toxicity, progression of disease, or a patient decided to discontinue treatment. There were seven patients with measurable disease and 15 with evaluable disease; all were assessable for response and toxicity. A total of 113 cycles of treatment were given, for a median of three cycles (range, 1- 26 cycles). Myelosuppression was the most frequent toxicity. Eighteen of 21 patients (86%) experienced grade 3 or 4 neutropenia during the initial treatment cycle. The median neutrophil nadir was 0.5 x 103/μl (range, 0.11.6 x 103/μl), and the median platelet nadir was 127 x 103/μl (range, 18-460 X 103/μl). Other toxicities more than grade 2 included malaise (two patients), and anorexia, infection, fever, pulmonary, and cardiac in one patient each. There were no objective responses, and 18 patients had stable disease for a median of 74 days. The median survival for all patients was 230 days, with 23% alive at 1 year. Topotecan as administered in this trial is reasonably well tolerated; however, the response rate was insufficient to warrant additional study in pleural mesothelioma.

KW - Mesothelioma

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0031793811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031793811&partnerID=8YFLogxK

U2 - 10.1097/00000421-199812000-00017

DO - 10.1097/00000421-199812000-00017

M3 - Article

C2 - 9856666

AN - SCOPUS:0031793811

VL - 21

SP - 610

EP - 613

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 6

ER -